I was reading over the last PR again. This part s
Post# of 36537
We will be testing the antibodies in virus neutralization assays to select the peptides for the vaccine, and in a cellular assay that models the cytokine storm in order to eliminate peptides that may cause an adverse immunologic response. With the results from our broad and proprietary immunological screening program, which we anticipate having in June, we will have an early indication of the immunologic efficacy and safety of an Ii-Key-SARS-CoV-2 peptide vaccine before our clinical trials even start